Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
Journal of Diabetes · 2025
DOI: 10.1111/1753-0407.70054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes, 2025. Verfasst von Marwa Al-Badri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Joslin Diabetes Center, Affiliated With Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Weight Loss, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glycated Hemoglobin. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are established treatment options for type 2 diabetes (T2D). In addition to their glycemic benefit, GLP‐1 RAs also induce weight loss by suppressing appetite via hypothalamic pathways. However, it remains unclear whether weight reduction is the primary driver of glycemic improvement.
Methods
We retrospectively evaluated 256 patients with T2D who were treated with exenatide ( n = 84), dulaglutide ( n = 99), or semaglutide ( n = 73) for 2.5 years without interruption in real‐world clinical practice. Body weight and A1C were measured every 6 months. Baseline characteristics included an average age of 61.8 ± 11.9 years, 51.5% female, diabetes duration of 12.9 ± 8.3 years, weight of 103.1 ± 20.7 kg, BMI of 35.7 ± 7.5 kg/m 2 , and A1C of 8.2% ± 1.5%. Patients were stratified into tertiles based on percentage weight change at 2.5 years within the overall cohort and for each GLP‐1 RA group.
Results
The first tertile experienced an average weight loss of −12.2% ± 5.7% ( p < 0.0001), the second tertile lost −3.5% ± 1.4% ( p < 0.0001), and the third tertile gained +2.8% ± 3.4% ( p < 0.0001). The average changes in A1C were − 0.98 ± 1.8% ( p < 0.0001), −0.56% ± 1.4% ( p < 0.001), and −0.19% ± 1.9% ( p = 0.4), respectively. A1C strongly correlated with weight change ( p < 0.001). The same observations were reproducible in each medication group.
Conclusions
These findings suggest that the long‐term improvement in glycemic control associated with GLP‐1 RA therapy is primarily driven by weight loss rather than any other intrinsic effect of GLP‐1 RA. This highlights the importance of weight reduction as a key therapeutic target for optimizing glycemic outcomes in patients with T2D receiving GLP‐1 RAs. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joslin Diabetes Center, Affiliated With Harvard Medical School, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Marwa Al-Badri, Shilton Dhaver
Förderung
- NIDDK NIH HHS
Zitieren
APA
Al-Badri, M., Dhaver, S., & Hamdy, O. (2025). Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70054
Vancouver
Al-Badri M, Dhaver S, Hamdy O. Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice. Journal of Diabetes. 2025. doi:10.1111/1753-0407.70054
BibTeX
@article{AlBadri2025,
author = {Al-Badri, Marwa and Dhaver, Shilton and Hamdy, Osama},
title = {Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice},
journal = {Journal of Diabetes},
year = {2025},
doi = {10.1111/1753-0407.70054}
}
EUVIMED